1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol

BACKGROUND: Cefiderocol (CFDC) is a siderophore cephalosporin with broad coverage of aerobic Gram-negative (GN) bacteria. Provisional breakpoints (BP) were approved by CLSI in 2018, with FDA and EUCAST providing clinical BP in 2019 and 2020, respectively; however, BPs differ markedly between organiz...

Full description

Saved in:
Bibliographic Details
Published in:Open Forum Infect Dis
Main Authors: Yamano, Yoshinori, Takemura, Miki, Longshaw, Christopher, Echols, Roger
Format: Artigo
Language:Inglês
Published: Oxford University Press 2020
Subjects:
Poster Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776267/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1453
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items